Concepedia

Dexiu Bu

DB

4

Publications

195

Citations

4

H-Index

2018

Active since

Affiliations

Novartis (United States)(Current)

Dana-Farber Cancer Institute

University of Pennsylvania

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

Dexiu Bu is an author at Novartis (United States) specializing in t cell immunity, medicine, and tumor immunity.

ORCID

Top concepts

Publications per year

2018–2023

4

Publications

4

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma

Dexiu Bu, Reshma Singh, Eugene Choi et al. · Oncotarget · 2018 · 70 citations · Full text

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya et al. · Blood Cancer Discovery · 2022 · 69 citations · Full text

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).

Adam S. Sperling, Benjamin A. Derman, Sarah Nikiforow et al. · Journal of Clinical Oncology · 2023 · 34 citations

, , +14

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Adam S. Sperling, Sarah Nikiforow, Omar Nadeem et al. · Blood · 2021 · 22 citations

Rows per page

1–4 of 4